By Imma Tinat 
Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
| April Rank | March Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 4,427 | 498 | 19 |
| 2 | 2 | Moderna | 2,129 | 95 | 1 |
| 3 | 5 | AstraZeneca | 985 | 301 | 29 |
| 4 | 4 | Johnson & Johnson | 658 | 173 | 15 |
| 5 | 11 | Abbott | 476 | 470 | 11 |
| 6 | 7 | GSK | 396 | 124 | 31 |
| 7 | 16 | Merck & Co | 314 | 121 | 2 |
| 8 | 13 | Bayer | 275 | 79 | 12 |
| 9 | 9 | Roche | 262 | 113 | 45 |
| 10 | 15 | Gilead Sciences | 247 | 101 | 1 |
| 11 | 12 | Novartis | 231 | 161 | 5 |
| 12 | 8 | Sanofi | 218 | 134 | 37 |
| 13 | 3 | Lilly | 202 | 125 | 0 |
| 14 | 6 | Novo Nordisk | 180 | 123 | 4 |
| 15 | 10 | AbbVie | 159 | 113 | 4 |
| 16 | 17 | Biogen | 158 | 100 | 5 |
| 17 | 14 | Takeda | 120 | 110 | 0 |
| 18 | 24 | Otsuka | 107 | 59 | 0 |
| 19 | 18 | Eisai | 107 | 85 | 0 |
| 20 | 20 | Amgen | 85 | 62 | 5 |
| 21 | 22 | BMS | 74 | 64 | 1 |
| 22 | 21 | Boehringer Ingelheim | 63 | 36 | 0 |
| 23 | 26 | Astellas | 62 | 50 | 0 |
| 24 | 23 | Fresenius | 56 | 21 | 4 |
| 25 | 19 | Daiichi Sankyo | 53 | 18 | 6 |
| 26 | 25 | Stada | 45 | 0 | 0 |
| 27 | 35 | Servier | 42 | 38 | 18 |
| 28 | 28 | Vertex | 34 | 33 | 0 |
| 29 | 39 | Merck KGaA | 33 | 23 | 9 |
| 30 | 31 | Regeneron | 30 | 19 | 3 |
| 31 | 41 | Menarini | 28 | 23 | 19 |
| 32 | 30 | UCB | 20 | 13 | 8 |
| 33 | 36 | Bausch | 19 | 4 | 0 |
| 34 | 27 | Viatris | 18 | 2 | 0 |
| 35 | 32 | Organon | 14 | 0 | 0 |
| 36 | 34 | Jazz Pharmaceuticals | 13 | 0 | 0 |
| 37 | 29 | Teva | 9 | 7 | 2 |
| 38 | 40 | Grifols | 8 | 1 | 0 |
| 39 | 33 | Ipsen | 7 | 5 | 0 |
| 40 | 38 | CSL | 7 | 7 | 0 |
| 41 | 42 | Sun | 6 | 4 | 0 |
| 42 | 42 | CSPC | 3 | 0 | 0 |
| 42 | 37 | Alexion | 3 | 3 | 0 |
| 44 | 44 | Kyowa Kirin | 2 | 0 | 0 |
| 45 | 45 | Jiangsu Hengrui | 1 | 0 | 0 |
| 50 | 50 | Aurobindo | 1 | 0 | 0 |
| 50 | 50 | Endo | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Shanghai | 0 | 0 | 0 |
| 50 | 50 | Sumitomo Dainippon | 0 | 0 | 0 |
The latest insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by eHCPs on Twitter in April 2023 were Pfizer, Moderna, AstraZeneca, Johnson & Johnson and Abbott.
CREATION.co identified 10,580 eHCP mentions of pharmaceutical companies online in April 2023, decreasing by 17% from the previous month.
A chemist shared the news that Moderna and MSD’s collaborative vaccine against melanoma has been designated as a breakthrough therapy by the FDA. This garnered retweets from over 90 eHCPs on Twitter.
Moderna anuncia su vacuna contra el cáncer (melanoma).
La compañía anunció que su vacuna ARNm-4157/V940 personalizada y en investigación contra el cáncer, en combinación con KEYTRUDA, la terapia anti-PD-1 de Merck, ha sido designada por la FDA como terapia innovadora. Esto
1/ pic.twitter.com/ncTYEGKsMS— Rosario in Paris 𓂃 ᥫ᭡ (@chayito09) April 15, 2023
Roche and Eli Lilly received positive remarks from eHCPs on their collaboration for the early detection of Alzheimer’s. This gathered a lot of conversations around the disease with eHCPs sharing posts either creating awareness or simply discussing other treatment options for Alzheimer’s.
Roche ve Eli Lilly Alzheimer'da erken teşhiste işbirliği yapacakmış.
👏👏👏
Etkili bir ilacı olmayan hastalığın erken döneminde kullanılacak bir ilaç geliştirmiş olmalılar.— Ahmet Rasim Küçükusta (@drahmetrasim) April 11, 2023
eHCPs discussed the benefits of tirzepatide, the “next-generation obesity drug” by Eli Lilly and shared results of the data from the SURMOUNT-2 study, showing efficacy.
Eli Lilly’s next-generation obesity drug helped patients lose up to 34 pounds in clinical trial – MarketWatch https://t.co/8sKqiNi9lR
— Dr. Martin Binks (@DrBinks) April 28, 2023
The top shared links by HCPs when mentioning a Top 50 pharma company discussed:
- A YouTube video by an online news show discussing Bristol Myers Squibb’s product, Abilify.
- An online news article sharing information about a protest held against Gilead.
- An online newspaper about Fresenius promising two million to a former deputy if he obtained contracts from a hospital.
In April, eHCPs reacted positively to pharmaceutical companies coming together to collaborate and work towards a goal in providing treatments to different therapy areas.
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology notes:
-
- In April 2023, CREATION Pinpoint® identified 10,580 healthcare professional authored tweets from 4,419 individual HCPs mentioning a Top 50 Pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 April and 30 April 2023.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In April 2023, 211 of these posts mentioned Janssen.
The Top 50 Pharma tracker archive
March 2022: eHCPs celebrate Eli Lilly for capping the cost of insulin
December 2022: HCPs celebrate the Moderna and Merck combination melanoma vaccine and immunotherapy
November 2022: HCPs actively discussed issues concerning mRNA and bivalent COVID-19 vaccines
October 2022: HCPs actively discussed issues concerning mRNA and bivalent COVID-19 vaccines
September 2022: Top 50 Pharma Tracker: Bivalent vaccine data and new treatments drive HCP conversation
August 2022: Top 50 Pharma Tracker: HCPs discuss bivalent vaccine approval in the UK and advances in obesity treatment.
June 2022: Top 50 Pharma Tracker: HCPs share mixed opinions on COVID-19 vaccines and treatment data
April 2022: HCPs celebrate the success of Lilly’s tirzepatide for obesity and discuss COVID-19 vaccine efficacy
March 2022: HCPs compare immune responses of T cell, B cell, and Antibodies to different COVID-19 vaccines.
February 2022: HCPs discuss Healthcare inequity and vaccination of under 5 year olds
January 2022: HCPs get political when discussing Regeneron’s COVID-19 treatment
December 2021: Omicron variant dominates HCP conversation in December 2021
November 2021 : HCPs discuss trial data of Pfizer’s COVID-19 booster vaccine and oral treatment
October 2021 : Pfizer most discussed company with booster and children’s COVID-19 jabs
